Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Makes biosimilar drugs cheaper and easier to access for patients.
The problem
Biosimilar drugs cost too much and patients struggle to afford them. These drugs could be cheaper alternatives to expensive biologics.
The proposal
The bill likely aims to reduce costs and barriers for biosimilar medications through pricing changes, insurance coverage rules, or approval process improvements.
The impact
Patients needing expensive biologic medicines, insurance companies, pharmaceutical makers, and healthcare systems. Affects drug affordability and access nationwide.
Biosimilars are cheaper copies of expensive biologic drugs. Making them more accessible means patients pay less for medicines they need. This helps people afford treatment.
When patients use cheaper biosimilar alternatives, insurance companies and government programs spend less money. This could lower everyone's healthcare costs over time.
More biosimilars in the market means drug companies compete on price. This competition naturally pushes prices down and gives patients more options.
When medicines cost less, more people can afford to buy them. This means more patients can actually receive the care they need.
Pharmaceutical companies make less money when cheaper alternatives exist. This could reduce their funding for new drug research and development in the future.
If companies know biosimilars will quickly become cheaper alternatives, they might invest less in creating new medicines. Less investment means fewer new treatments discovered.
If approval processes are rushed or standards lowered, cheaper biosimilars might not work as well or could have hidden safety issues. Patients need effective, safe medicines.
Insurance companies might force patients to use cheaper biosimilars even when original medicines work better for them. This limits patient choice in treatment options.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.